Ligand validation:5AMJ

EF2: S-Thalidomide

EF2 is a Ligand Of Interest in 5AMJ designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5AMJ_EF2_A_151	92%	5%	0.081	0.971	2.65	2.76	8	10	0	0	100%	1
5AMJ_EF2_B_151	90%	6%	0.091	0.974	2.85	2.16	5	11	0	0	100%	1
5AMI_EF2_B_151	95%	4%	0.069	0.975	2.56	3.03	6	13	0	0	100%	1
7PSO_EF2_B_202	91%	7%	0.083	0.97	2.12	2.68	5	12	0	0	100%	1
4V2Y_EF2_B_151	91%	4%	0.072	0.958	2.78	3.08	6	13	0	0	100%	1
4V32_EF2_B_151	88%	1%	0.09	0.966	4.16	4.22	9	17	0	0	100%	1
5AMH_EF2_A_151	87%	12%	0.082	0.954	1.94	2.1	8	10	0	0	100%	1
5YJ0_EF2_n_501	93%	12%	0.07	0.963	2.17	1.91	4	11	0	0	100%	1
4TZC_EF2_A_504	90%	2%	0.082	0.966	3.77	3.24	5	12	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.